Healthy and diseased cells are marked by the presence of misfolded protein production, which can result in cellular toxicity and catastrophic tissue injury.
Link leverages a deep biological understanding of neurodegenerative disease progression to target toxic protein aggregate pathologies.
Alzheimer's and Parkinson's disease affect millions of individuals worldwide and both are characterized by a buildup of incorrectly folded proteins in nerve cells.
The aggregated proteins trigger a cascade of cellular events causing neuronal malfunction and/or death, ultimately resulting in the cognitive and behavioral pathologies characteristic of the diseases.
Link Medicine History
Link Medicine was founded in 2005 by Peter Lansbury, Ed Rudman, and Adam Rosenberg, who shared the same philosophy of neurodegenerative disease treatment – address the root cause rather than the symptoms.
This shared vision has allowed Link to advance novel approaches to treating neurodegenerative diseases, through pre-clinical and early clinical testing. We anticipate that Link will enter human clinical testing in a relevant disease population in 2010.
Dedicated to Neurodegenerative Disease
There is growing appreciation in the scientific community of the role of toxic protein aggregates in many neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Link's therapeutic approach is to target the common causative feature of this disease class by restoring the natural balance between the production and clearance of these toxic protein aggregates, slowing or halting the progression of these diseases. Current therapies can only ameliorate the symptoms, usually resulting in a modest and ultimately transient symptomatic improvement. Learn More...
Link in the News